Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
NCT02628704
Withdrawn
Double-blind study will compare the efficacy and assess safety of selinexor plus carfilzomib (Kyprolis®) plus low-dose dexamethasone versus placebo plus carfilzomib plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2023
Locations: James R. Berenson MD, Inc, West Hollywood, California +1 locations
Conditions: Multiple Myeloma
Register for Updates
Selinexor Treatment of Refractory Myeloma
NCT02336815
Completed
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2023
Locations: University of Alabama, Birmingham, Alabama +60 locations
Conditions: Multiple Myeloma
Register for Updates
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
NCT03252600
Unknown
This randomized phase II trial studies how well lenalidomide, dexamethasone, and eotuzumab with or without cyclophosphamide work in treating patients with primary amyloidosis that has come back after a period of improvement. Drugs used in chemotherapy, such as lenalidomide, dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2023
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +4 locations
Conditions: Recurrent Primary Amyloidosis
Register for Updates
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
NCT04130802
Completed
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract surgery. The primary objective is to evaluate the efficacy and safety of OCS-01 compared to placebo and the secondary objective is to evaluate the optimal dosing frequency (once a day \[QD\] or twice a day \[BID\]).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2023
Locations: Medical cennre, Petaluma, California +3 locations
Conditions: Inflammation Corneal, Pain, Postoperative
Register for Updates
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
NCT02186834
Completed
The main purpose of this study is to determine the recommended doses of selinexor in combination with liposomal doxorubicin and dexamethasone for patients with relapsed and refractory myeloma. In addition, the study will assess whether this combination with effective for patients with multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/29/2022
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida +1 locations
Conditions: Multiple Myeloma
Register for Updates
Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes
NCT02469519
Completed
This trial hopes to prospectively evaluate the impact of one versus two courses of antenatal steroids on the incidence of major neonatal morbidity in pregnant women with pre-labor premature rupture of the membranes.
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
12/14/2022
Locations: University of South Alabama Medical Center, Mobile, Alabama +8 locations
Conditions: Premature Birth
Register for Updates
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
NCT03481556
Terminated
This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma to combination regimens of melflufen with currently approved agents. Patients will receive either melflufen+dexamethasone+bortezomib or melflufen+dexamethasone+daratumumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/14/2022
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +15 locations
Conditions: Multiple Myeloma
Register for Updates
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
NCT03651128
Active Not Recruiting
This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2022
Locations: Local Institution - 109, Birmingham, Alabama +59 locations
Conditions: Multiple Myeloma
Register for Updates
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01005914
Terminated
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects of giving pegaspargase together with combination chemotherapy and to see how well it works in treating patients with newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
12/13/2022
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Leukemia
Register for Updates
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
NCT04223661
Withdrawn
The purpose of this study is to determine if using a subject's baseline frailty score to guide the dosing of lenalidomide in a combination with dexamethasone and daratumumab (DRd lite).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
12/06/2022
Locations: VA Roudebush Medical Center, Indianapolis, Indiana
Conditions: Multiple Myeloma
Register for Updates
The Effects of Dexamethasone on the Time to Pain Resolution in Dental Periapical Abscess
NCT03005522
Completed
An individual's quality of life can be seriously affected by the severity of dental pain. The emergency department is a common place to find those seeking relief from their dental pain- often times seeking removal of the affected tooth, dental anesthetic injections or oral pain medications. There are a number of dental infections that cause this type of debilitating pain. One such dental infection is termed periapical abscess. This infection involves the tooth pulp. These infections can arise in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2022
Locations: Banner University Medical Center, Tucson, Arizona
Conditions: Dental Research, Pharmaceutical Preparations, Dental
Register for Updates
Comparative Trial Via Tranforaminal Approach Versus Epidural Catheter Via Interlaminar Approach
NCT03382821
Completed
Do cervical epidural steroid injections done by transforaminal catheter targeted approach improve pain and function in patients with cervical radicular pain?
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/22/2022
Locations: University of Utah Orthopaedic Center, Salt Lake City, Utah
Conditions: Cervical Radiculopathy
Register for Updates